The FDA has approved eplontersen (Wainua) for treating polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis
The FDA has approved Wainua (eplontersen) for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis.
21, 2024, AstraZeneca and Ionis Pharmaceuticals announced the FDA approval of Wainua (eplontersen) for the treatment of the polyneuropathy of
Decem - AstraZeneca and Ionis announced the FDA approval of Wainua (eplontersen), for the treatment of the polyneuropathy of
Onpattro (patisiran) was both the first siRNA drug to ever receive FDA approval and the first The news that regulatory approval will be sought for eplontersen
On Decem, the FDA approved eplontersen under the brand WAINUA (eplontersen) granted regulatory approval in the U.S.
(Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's WAINUA (eplontersen)
Section 505(o)(3) of the FDCA authorizes FDA to require holders of approved drug and assess concentrations of eplontersen in breast milk.
Eplontersen has the following regulatory designation:8. the US FDA approval for the treatment of adults with polyneuropathy of hereditary.
Comments
What the hell would the FDA have to do with it? This is a piece of machinery. They would have NO say about it whatsoever.